Advertisement
Advertisement
U.S. Markets open in 7 hrs 4 mins
Advertisement
Advertisement
Advertisement
Advertisement

Avidity Biosciences, Inc. (RNA)

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
Add to watchlist
18.75+0.21 (+1.13%)
At close: 04:00PM EDT
18.00 -0.75 (-4.00%)
After hours: 05:15PM EDT
Advertisement

Avidity Biosciences, Inc.

10578 Science Center Drive
Suite 125
San Diego, CA 92121
United States
858 401 7900
https://www.aviditybiosciences.com

Sector(s)Healthcare
IndustryBiotechnology
Full Time Employees125

Key Executives

NameTitlePayExercisedYear Born
Dr. Troy Edward Wilson J.D., Ph.D.Co-Founder & Chairman65kN/A1969
Ms. Sarah BoycePres, CEO & Director1MN/A1972
Mr. Michael F. MacLeanCFO & Chief Bus. Officer650.38kN/A1966
Dr. W. Michael Flanagan Ph.D.Chief Technical Officer1MN/A1962
Dr. Arthur A. Levin Ph.D.Chief Scientific Officer662.86k1.47M1954
Mr. Joseph T. BaroldiConsultant642.43kN/A1979
Prof. Mark E. DavisScientific Founder, Member of Scientific Advisory Board and Member of Board of Mang.sN/AN/AN/A
Dr. Frank McCormick Ph.D.Scientific Founder & Member of Scientific Advisory BoardN/AN/A1950
Ms. Kathleen GallagherSr. VP of Corp. Communications & Investor RelationsN/AN/AN/A
Dr. John W. Wallen IIIVP of Intellectual Property, Gen. Counsel & Sec.N/AN/A1958
Amounts are as of December 31, 2021 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Avidity Biosciences, Inc., a biopharmaceutical company, engages in the development of oligonucleotide-based therapies. It develops antibody oligonucleotide conjugates (AOC) that are designed to treat a range of serious diseases. The company's lead product candidate AOC 1001 is used for the treatment of myotonic dystrophy type 1, a rare monogenic muscle disease; AOC 1044 for the treatment of Duchenne Muscular Dystrophy; and AOC 1020 designed to treat facioscapulohumeral muscular dystrophy which are in preclinical stage. It also offers Lumizyme therapy for Pompe diseases. Avidity Biosciences, Inc. was incorporated in 2012 and is headquartered in San Diego, California.

Corporate Governance

Avidity Biosciences, Inc.’s ISS Governance QualityScore as of July 31, 2022 is 9. The pillar scores are Audit: 8; Board: 9; Shareholder Rights: 8; Compensation: 9.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.
Advertisement
Advertisement